Skip to content

Insulin and Muscle Fat Metabolism

Insulin and Muscle Fat Metabolism

Status
Terminated
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04759872
Enrollment
9
Registered
2021-02-18
Start date
2021-02-22
Completion date
2022-06-07
Last updated
2022-06-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Insulin Resistance, Metabolic Disease, Mitochondrial Metabolism, Overweight and Obesity, Sedentary Lifestyle

Brief summary

Our objective in this study is to identify the extent to which insulin drives the accumulation of lipids in skeletal muscle of humans. We will test the hypothesis that 4-hours of mild hyperinsulinemia will result in significant muscle lipid accumulation and that such effects will be similar in lean and overweight/obese humans.

Interventions

Participants will be administered a constant-rate insulin infusion (to induce mild hyperinsulinemia), with an infusion of dextrose to maintain blood glucose concentration (to maintain euglycemia).

Sponsors

Oregon State University
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
BASIC_SCIENCE
Masking
NONE

Intervention model description

Participants will be asked to complete 1 screening visit to determine eligibility. If participants remain eligible, they will be asked to complete 1 metabolic study visit.

Eligibility

Sex/Gender
ALL
Age
30 Years to 55 Years
Healthy volunteers
Yes

Inclusion criteria

* Age 30-55 years * Body mass index (BMI) 18-45 kg/m2 * Sedentary (\<1 hour of planned exercise per week)

Exclusion criteria

* Regular exercise (\>1 hour of planned exercise per week) * Smoking, tobacco or nicotine use within the last 1-year * Fasting glucose \>126mg/dL * Hypertension (systolic pressure \>140 mmHg or diastolic pressure \>90 mmHg) * Chronic metabolic or cardiovascular health conditions * Pregnant, nursing, irregular menses or post-menopausal * Lidocaine allergy * Certain medications * Diminished capacity for consent

Design outcomes

Primary

MeasureTime frameDescription
Changes in skeletal muscle lipid content during hyperinsulinemia compared with basal resting conditionsMuscle samples will be collected in basal and hyperinsulinemic conditions separated by ~4.5 hours during the metabolic study visitLiquid chromatography tandem mass spectrometry (targeted lipidomics) will be used to assess species-level changes in skeletal muscle lipid content in biopsy samples collected before and after the insulin infusion to induce mild hyperinsulinemia.

Secondary

MeasureTime frameDescription
Changes in skeletal muscle mitochondrial oxidative capacity during hyperinsulinemia compared with basal resting conditionsMuscle samples will be collected in basal and hyperinsulinemic conditions separated by ~4.5 hours during the metabolic study visitHigh-resolution respirometry will be used to assess changes in skeletal muscle mitochondrial oxidative capacity in biopsy samples collected before and after the insulin infusion to induce mild hyperinsulinemia.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026